Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
A medical expert claims Trump's bruised hand proves he is receiving monthly infusions for possible dementia, linking it to ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by ...
Eisai and partner BioArctic recently reported at the CTAD 2025 conference that long-term data for Leqembi (lecanemab) suggest early, continued treatment can substantially delay progression from mild ...
Pharmaceutical Technology on MSN
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...
Amid health speculations, US President Donald Trump confidently talks about his 'good memory' during the Kennedy Centre ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Japanese drugmaker Eisai and US biotech Biogen announced new data confirming the pharmacological effect of Leqembi (lecanemab ...
Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback